Genentech Plans Herceptin Early-Stage Breast Cancer Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.